NGAL Protein Levels in Simple Urine Test Reveal Sudden Kidney Failure Days Sooner than Current Tests
NEW YORK (June 2, 2008) – Walk into any emergency department complaining of chest pain and you are likely to have blood drawn. Within hours it should be clear whether you’ve had a heart attack, based on enzyme levels in your blood and whether those levels reveal the tissue damage normally associated with a heart attack or other major cardiac event.
Walk into any emergency department with life-threatening kidney damage and the story is not quite the same. First, no test can reveal kidney damage in an efficient and timely way. Since the current check for kidney damage, a blood test for creatinine, can take longer than one or two days to accumulate in clinically significant levels, irreversible damage might already have set in during the time between injury and diagnosis. Second, today’s standard creatinine test does not indicate the cause of the damage: Could an elevated serum creatinine be acute kidney failure from an emergent medication reaction or an underlying infection, or could it be kidney disease that was previously active, but now dormant?
Foreground: Medical students Matthew O’Rourke and Meghan Sise Background: Drs. T. Nickolas, J. Giglio, P. Cannetta and J. Barasch
To tackle the gap between injury, diagnosis and treatment, a unique team of basic scientists, physicians, medical and college students is focusing on a small protein found in the urine at the time of sudden kidney failure. The protein detects kidney injury one to two days sooner than the creatinine test for renal failure. A simple urine test for the protein NGAL (neutrophil gelatinase-associated lipocalin) can help emergency department physicians more accurately and rapidly diagnose kidney failure, which can result in intensive care admission, dialysis, or even death. This fast and precise test will allow physicians to make evidence-based and potentially lifesaving treatment decisions.
The team, led by Jonathan Barasch, M.D., Ph.D., associate professor of medicine, and Thomas Nickolas, M.D. M.S., assistant professor of clinical medicine at Columbia University Medical Center, will publish the results of its study, conducted in the emergency department of NewYork-Presbyterian Hospital/Columbia University Medical Center, in the June 3 issue of the Annals of Internal Medicine.
If testing for NGAL is broadly implemented in emergency departments, doctors may be able to better distinguish between acute kidney injury that needs to be treated aggressively and chronic disease, which may not require an emergent treatment and is more common in many chronic illnesses, such as diabetes. Not adequately diagnosing a more severe problem can be life-threatening: Approximately 65 percent of patients with NGAL protein in the urine will require care by a nephrologist, another 32 percent will need dialysis, and 29 percent will require care in the intensive care unit, the study’s authors have found.
“NGAL was diagnostic in a single test, whereas a single serum creatinine test can’t discriminate acute kidney failure from chronic kidney disease,” says Dr. Barasch, who found a connection between NGAL and the kidneys several years ago. “By showing that NGAL distinguishes acute kidney injury from other types of problems, this trial is a first step toward applying this protein to everyday clinical practice.”
In their trial with more than 600 patients who came to the emergency department at NYP/Columbia, researchers found NGAL levels in patients later diagnosed with acute kidney failure were 30 times higher than patients who did not have renal injury.
Dr. Jonathan Barasch (right) with Dr. Pietro Cannetta outside the emergency department at CUMC/NYPH
“This level of accuracy is encouraging,” said Pietro Canetta, M.D., a resident at NYP/Columbia who helped run the study at the emergency department. “Getting this quality of information so early in a patient’s course, from just a single drop of urine, could be very helpful to clinicians. It provides concrete data in a clinical situation which is often dominated by guesswork and uncertainty.”
Previous studies in children and adults by Prasad Devarajan, M.D, director of nephrology and hypertension at Cincinnati Children’s Hospital, have shown that urine NGAL is well-defined and massively expressed in cases of acute kidney injury. Other members of the team include Jun Yang, M.D., Ph.D., a resident at St. Luke’s-Roosevelt Hospital Center; Columbia University College of Physicians & Surgeons students Matthew O’Rourke and Meghan Sise; and college students Nicholas Barasch and Charles Buchen.
This work would not have been possible without the generous support of the Emerald Foundation. The NIH Clinical and Translational Science Award (CTSA) grant that Columbia received two years ago is also providing key support in translating Dr. Barasch’s bench findings into bedside applications.
CUMC and Cincinnati Children’s Hospital Medical Center have licensing agreements in place with Biosite and Abbott Diagnostics, and these companies have also provided analysis tools to measure NGAL levels.
Columbia University Medical Center provides international leadership in basic, pre-clinical and clinical research, in medical and health sciences education, and in patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians & Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Established in 1767, Columbia’s College of Physicians & Surgeons was the first institution in the country to grant the M.D. degree. Among the most selective medical schools in the country, the school is home to the largest medical research enterprise in New York State and one of the largest in the country. For more information, please visit www.cumc.columbia.edu.
- ### -